EsoCap reports positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis ESO-101, EsoCap's lead product candidate, consists of a capsule with a rolled-up, thin mucoadhesive film with the anti-inflammatory corticosteroid, mometasone furoateEsoCap's novel targeted delivery...

OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel Based on large multi-center study with over 1,800 patient samplesPrimary endpoint for Unyvero UTI for urinary tract infection was successfully met and shows overall weighted average sensitivity of...

Independent data review commences for Phase 2 trial of psilocybin-assisted psychotherapy for anxiety MELBOURNE, Australia, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing proprietary...